DiaMedica's Q2 2025: Unpacking Contradictions in Stroke Study Timelines and Preeclampsia Prospects

Stroke study enrollment and timelines, target indication and label expansion for preeclampsia study, preeclampsia study progression, stroke study enrollment and progress are the key contradictions discussed in DiaMedica Therapeutics' latest 2025Q2 earnings call.



Preclinical Program Advancement:
- DiaMedica reported positive interim results from Part 1a of its Phase II preeclampsia trial, demonstrating significant reductions in both systolic and diastolic blood pressure with its lead candidate DM199.
- This progress is attributed to DM199's ability to enhance blood flow and vascular health, addressing the underlying ischemic condition without placental transfer.

Stroke Program Milestones:
- Enrollment in the ReMEDy2 stroke trial is currently above the 25th percentile milestone and is steadily advancing towards the halfway mark, with data from the first 200 patients expected by Q2 2026.
- The progress is driven by the successful poster presentation at the European Stroke Organization Conference and positive DSMB reviews.

Financial Performance and Cash Runway:
- As of June 30, 2025, DiaMedica's cash position was $30 million, with a pro forma cash position of approximately $60 million after a private placement.
- The increase in R&D expenses ($5.8 million in Q2 2025 compared to $3.9 million in Q2 2024) is due to the expansion of the ReMEDy2 clinical trial and the addition of new team members.

Leadership and Expertise Expansion:
- Julie Krop, a medical professional with experience in clinical and commercial-stage organizations, joined DiaMedica as the new Chief Medical Officer.
- Her appointment brings valuable expertise to the team as it continues to advance DM199 for both preeclampsia and stroke indications.